Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: RPL28

Summary for RPL28

Gene information	Gene symbol	RPL28
	Ensembl ID	ENSG00000108107
	Entrez ID	6158
	Gene name	ribosomal protein L28
	Synonyms	FLJ43307\|L28
	Gene type	protein_coding
	UniProtAcc	P46779

Top

Dataset with differentially expressed gene: RPL28

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	2.11804	0.00e+00
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.500048	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.36236	3.27e-04
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	-0.293056	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.472509	6.41e-27
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.272432	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	-0.488309	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.622048	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.461481	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.837619	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.454473	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.523911	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	-0.465014	3.18e-04
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.647849	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	pDCs	-0.755622	5.17e-12
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	pDCs	-0.308041	2.46e-03
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.415367	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.512254	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.723574	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.329917	2.06e-25
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	1.01727	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	cDCs	0.25236	2.60e-04
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.411428	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.250067	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	-0.354853	1.82e-24
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.294457	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	pDCs	0.510376	8.74e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	0.496359	1.42e-20
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.499188	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.52292	1.51e-17
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.514254	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.269384	6.51e-14
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.281219	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.410636	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.92393	9.33e-37
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.353817	4.23e-14
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.270665	6.29e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.368306	3.61e-13
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.487848	1.85e-30
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.32063	2.06e-11
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.586223	1.20e-29
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD4+ T cells	-0.318277	5.84e-05
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.327112	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.298008	9.26e-20
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.455329	1.68e-16
GSE149214	PC9 cell line	Cell line	Lung cancer	EGFR-mutated non-small cell lung cancer (NSCLC)	Targeted therapy	erlotinib	NA	Malignant cells	-0.631972	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.254041	1.09e-25
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	-0.301477	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	pDCs	-0.471716	4.44e-02
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	1.13679	2.88e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.261157	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.69087	1.35e-09
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	-0.342286	2.02e-09
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.487185	4.65e-23
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Mono/Macro	-0.547653	1.91e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-0.598968	2.10e-13
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.501363	3.92e-25
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	0.43084	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	0.619295	0.00e+00
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.467535	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	-0.298715	1.81e-06
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.345774	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	-0.365151	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.463008	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-2.21457	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-2.22064	0.00e+00

Top

Expression of RPL28 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to RPL28

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating RPL28

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
RPL28	hsa-miR-4492	93.3985	NM_000991
RPL28	hsa-miR-4319	91.3882	NM_001136137
RPL28	hsa-miR-6728-3p	91.2799	NM_000991
RPL28	hsa-miR-3177-5p	89.3282	NM_001136135
RPL28	hsa-miR-4296	88.185	NM_000991
RPL28	hsa-miR-4283	88.028	NM_001136134
RPL28	hsa-miR-125a-5p	87.7578	NM_001136137
RPL28	hsa-miR-125b-5p	87.7578	NM_001136137
RPL28	hsa-miR-8073	87.2816	NM_001136137
RPL28	hsa-miR-221-5p	87.2816	NM_001136137
RPL28	hsa-miR-4498	87.2497	NM_000991
RPL28	hsa-miR-5001-5p	84.3737	NM_000991
RPL28	hsa-miR-661	83.795	NM_001136134
RPL28	hsa-miR-762	83.5978	NM_000991
RPL28	hsa-miR-1306-5p	83.2018	NM_000991
RPL28	hsa-miR-4685-3p	82.5165	NM_000991
RPL28	hsa-miR-4287	82.5165	NM_000991
RPL28	hsa-miR-6887-3p	81.8347	NM_000991
RPL28	hsa-miR-4322	81.0898	NM_000991
RPL28	hsa-miR-4265	81.0898	NM_000991
RPL28	hsa-miR-3187-5p	80.8996	NM_000991
RPL28	hsa-miR-9900	80.8214	NM_001136136
RPL28	hsa-miR-1285-3p	80.7865	NM_000991
RPL28	hsa-miR-5189-5p	80.7865	NM_000991
RPL28	hsa-miR-4679	80.5938	NM_001136135
RPL28	hsa-miR-507	80.2242	NM_000991
RPL28	hsa-miR-6860	80.0892	NM_000991

Page: 1

Top

Motifs and transcription factors (TFs) regulating RPL28

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
RPL28	transfac_pro__M01735	PITX3 (directAnnotation).
RPL28	cisbp__M01809	FOSL2 (inferredBy_Orthology).
RPL28	transfac_pro__M05818	ZNF627 (directAnnotation).
RPL28	taipale_tf_pairs__HOXB13_ETV1_RSCGGAARYNNTAAAN_CAP_repr	ETV1; HOXB13 (directAnnotation).
RPL28	transfac_pro__M06858	ZNF224 (directAnnotation).
RPL28	jaspar__MA0775.1	MEIS3 (directAnnotation).
RPL28	transfac_pro__M06822	ZNF532 (inferredBy_Orthology).
RPL28	transfac_pro__M06382	ZNF773 (directAnnotation).
RPL28	kznf__ZNF582_Imbeault2017_OM_MEME	ZNF582 (directAnnotation).
RPL28	swissregulon__mm__Ehf	EHF (inferredBy_Orthology).
RPL28	transfac_pro__M06149	ZNF132 (directAnnotation).
RPL28	metacluster_155.3	PLAG1 (directAnnotation). PLAG1 (inferredBy_Orthology).
RPL28	transfac_pro__M05700	ZNF19 (directAnnotation).
RPL28	taipale_tf_pairs__GCM1_SOX2_RTRSGGGNNNATTGTKY_CAP_repr	GCM1; SOX2 (directAnnotation).
RPL28	tfdimers__MD00445	GTF2IRD1; TFAP2C (directAnnotation).
RPL28	metacluster_138.1	ZFP14; ZFP14 (directAnnotation).
RPL28	transfac_pro__M06340	ZNF790 (directAnnotation).
RPL28	hocomoco__DPRX_HUMAN.H11MO.0.D	DPRX (directAnnotation).
RPL28	transfac_pro__M06086	ZNF17 (directAnnotation).
RPL28	metacluster_173.2	ATF3; ATF6; ATF6; ATF6; ATF6; ATF6; ATF6; ATF6B; ATF6B; ATF6B; BATF3; CREB3; CREB3; CREB3; CREB3; CREB3; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L2; CREB3L4; XBP1; XBP1; XBP1; XBP1 (directAnnotation). ATF1; ATF1; ATF1; ATF1; ATF6; ATF6; ATF6; ATF6; ATF6; ATF6B; ATF6B; ATF6B; ATF6B; CREB1; CREB1; CREB3; CREB3; CREB3; CREB3; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L1; CREB3L2; CREB3L2; CREB3L2; CREB3L2; CREB3L2; CREB3L3; CREB3L3; CREB3L3; CREB3L3; CREB3L4; CREB3L4; CREB3L4; CREB3L4; CREM; CREM; CREM; CREM (inferredBy_Orthology).
RPL28	metacluster_0.2	CRX; CRX; CRX; CRX; CRX; CRX; CRX; CRX; DMBX1; DMBX1; DPRX; GSC; GSC; GSC; GSC; GSC; GSC; GSC2; GSC2; GSC2; OTX1; OTX1; OTX1; OTX1; OTX1; OTX1; OTX2; OTX2; OTX2; OTX2; OTX2; OTX2; OTX2; OTX2; PITX1; PITX1; PITX1; PITX1; PITX1; PITX1; PITX1; PITX1; PITX1; PITX1; PITX2; PITX2; PITX2; PITX2; PITX2; PITX2; PITX2; PITX2; PITX2; PITX2; PITX3; PITX3; PITX3; PITX3; RAX; RHOXF1; RHOXF1; RHOXF1; RHOXF2; RHOXF2 (directAnnotation). CRX; CRX; CRX; CRX; CRX; DMBX1; DMBX1; DMBX1; GSC; GSC; OTX1; OTX1; OTX2; OTX2; PITX1; PITX1; PITX1; PITX3 (inferredBy_Orthology).
RPL28	taipale_tf_pairs__ETV2_HOXB13_NCCGGAAGTYRTAAAN_CAP	ETV2; HOXB13 (directAnnotation).
RPL28	taipale_tf_pairs__NR1I2_RGTTCRNNNRGTTC_HT	NR1I2 (directAnnotation).
RPL28	transfac_pro__M06943	PBX3 (directAnnotation).
RPL28	taipale_tf_pairs__POU2F1_ELK1_NCCGGATATGCAN_CAP_repr	ELK1; POU2F1 (directAnnotation).
RPL28	kznf__ZNF136_Imbeault2017_RP_RCADE	ZNF136 (directAnnotation).
RPL28	dbtfbs__SETDB1_HEK293_ENCSR348AGV_merged_N1	SETDB1 (directAnnotation).
RPL28	taipale_tf_pairs__PITX1_EOMES_GGATTANNARGTGTKN_CAP_repr	EOMES; PITX1 (directAnnotation).
RPL28	transfac_pro__M06749	ZNF222 (directAnnotation).
RPL28	transfac_pro__M04826	EP300 (directAnnotation).
RPL28	taipale_tf_pairs__ETV2_FOXI1_RSCGGATGTTKW_CAP	ETV2; FOXI1 (directAnnotation).
RPL28	taipale_tf_pairs__ERF_FOXI1_RSCGGATGTTKWN_CAP_repr	ERF; FOXI1 (directAnnotation).
RPL28	transfac_pro__M06550	ZNF519 (directAnnotation).
RPL28	metacluster_161.16	NKX3-2 (directAnnotation).
RPL28	transfac_pro__M06552	ZNF420 (directAnnotation).
RPL28	taipale_cyt_meth__NKX2-3_NTCGTTGAN_eDBD_meth	NKX2-3 (directAnnotation).
RPL28	taipale_cyt_meth__POU6F1_NTAATKAGSN_FL_meth	POU6F1 (directAnnotation).
RPL28	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
RPL28	kznf__ZNF737_Imbeault2017_OM_MEME	ZNF737 (directAnnotation).
RPL28	hdpi__ZBTB12	ZBTB12 (directAnnotation).
RPL28	transfac_pro__M00641	HSF1 (directAnnotation).
RPL28	taipale_tf_pairs__FLI1_MAX_RSCGGAANCACGTGN_CAP	FLI1; MAX (directAnnotation).
RPL28	transfac_pro__M06471	ZNF283 (directAnnotation).
RPL28	kznf__ZNF605_Imbeault2017_OM_RCADE	ZNF605 (directAnnotation).
RPL28	hdpi__SNAPC5	SNAPC5 (directAnnotation).
RPL28	transfac_pro__M00655	ETV4 (directAnnotation).
RPL28	taipale_cyt_meth__POU6F1_NATTATNNNNNNNATAATN_FL_repr	POU6F1 (directAnnotation).
RPL28	transfac_pro__M05976	ZNF223 (directAnnotation).
RPL28	jaspar__MA1998.1	PRDM14 (inferredBy_Orthology).
RPL28	jaspar__MA1943.1	HOXB13 (directAnnotation).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."